Compare FSK & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSK | RCUS |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.0B |
| IPO Year | 2008 | 2018 |
| Metric | FSK | RCUS |
|---|---|---|
| Price | $10.35 | $30.54 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 10 |
| Target Price | $13.19 | ★ $31.90 |
| AVG Volume (30 Days) | ★ 2.9M | 1.4M |
| Earning Date | 05-11-2026 | 05-05-2026 |
| Dividend Yield | ★ 18.82% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $247,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $45.62 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.72 | $7.92 |
| 52 Week High | $22.68 | $31.44 |
| Indicator | FSK | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 44.17 | 73.95 |
| Support Level | $9.85 | $19.78 |
| Resistance Level | $10.56 | N/A |
| Average True Range (ATR) | 0.27 | 1.63 |
| MACD | -0.06 | 0.77 |
| Stochastic Oscillator | 30.61 | 90.94 |
FS KKR Capital Corp is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company. The company's investment objectives are to generate current income and, to a lesser extent, long-term capital appreciation. The company's portfolio is comprised of investments in senior secured loans and second lien secured loans of private middle market U.S. companies and, to a lesser extent, subordinated loans and certain asset-based financing loans of private U.S. companies.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.